Published in BMJ Open on February 27, 2014
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thromb J (2015) 1.04
Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre. Kardiochir Torakochirurgia Pol (2015) 0.95
Emergency Abdominal Operations in the Elderly: A Multivariate Regression Analysis of 430 Consecutive Patients with Acute Abdomen. World J Surg (2015) 0.80
Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. Springerplus (2016) 0.75
Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland. Clin Epidemiol (2016) 0.75
Primary-care-based episodes of care and their costs in a three-month follow-up in Finland. Scand J Prim Health Care (2015) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol (2009) 3.68
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation (2011) 2.80
Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart (2000) 2.05
An update on regional variation in cardiovascular mortality within Europe. Eur Heart J (2008) 1.83
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol (2012) 1.79
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J (2011) 1.67
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost (2011) 1.59
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res (2008) 1.47
Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Curr Med Res Opin (2006) 1.05
Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology (2012) 1.05
Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother (2005) 1.02
The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract (2007) 1.00
Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost (2010) 0.95
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One (2012) 0.93
Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic. South Med J (2000) 0.84
Computerised assistance for warfarin dosage--effects on treatment quality. Eur J Intern Med (2012) 0.79
Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project. Heart (2009) 1.46
The functional response of a generalist predator. PLoS One (2010) 1.34
Risk factors for persistent frequent use of the primary health care services among frequent attenders: a Bayesian approach. Scand J Prim Health Care (2010) 1.12
Sensitivity to assumptions in models of generalist predation on a cyclic prey. Ecology (2007) 0.99
Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol (2011) 0.95
Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart (2007) 0.92
Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One (2012) 0.87
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol (2013) 0.83
Bayesian predictors of very poor health related quality of life and mortality in patients with COPD. BMC Med Inform Decis Mak (2013) 0.80
Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health (2011) 0.79
Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ (2013) 0.78
Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ (2011) 0.77
Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. BMJ Open (2012) 0.76
Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions. J Eval Clin Pract (2014) 0.75
[Indirect comparison and network meta-analyses--new tools for the assessment of evidence on the relative efficacy of drugs]. Duodecim (2011) 0.75
The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). Value Health (2011) 0.75